These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 28901796)

  • 21. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
    Barnett AH; Charbonnel B; Donovan M; Fleming D; Chen R
    Curr Med Res Opin; 2012 Apr; 28(4):513-23. PubMed ID: 22313154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
    Ekholm E; Hansen L; Johnsson E; Iqbal N; Carlsson B; Chen H; Hirshberg B
    Endocr Pract; 2017 Mar; 23(3):258-265. PubMed ID: 27849380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.
    Cook W; Bryzinski B; Slater J; Frederich R; Allen E
    Postgrad Med; 2013 May; 125(3):145-54. PubMed ID: 23748515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.
    Seino Y; Sasaki T; Fukatsu A; Imazeki H; Ochiai H; Sakai S
    Curr Med Res Opin; 2018 Jun; 34(6):981-994. PubMed ID: 29448833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial.
    Vilsbøll T; Ekholm E; Johnsson E; Dronamraju N; Jabbour S; Lind M
    Diabetes Care; 2019 Aug; 42(8):1464-1472. PubMed ID: 31167892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial.
    Yang W; Pan CY; Tou C; Zhao J; Gause-Nilsson I
    Diabetes Res Clin Pract; 2011 Nov; 94(2):217-24. PubMed ID: 21871686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period.
    Kadowaki T; Kondo K; Sasaki N; Miyayama K; Yokota S; Terata R; Gouda M
    Expert Opin Pharmacother; 2017 Sep; 18(13):1291-1300. PubMed ID: 28741385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment.
    Nowicki M; Rychlik I; Haller H; Warren ML; Suchower L; Gause-Nilsson I;
    Diabetes Obes Metab; 2011 Jun; 13(6):523-32. PubMed ID: 21332627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety.
    Jain R
    Adv Ther; 2015 Nov; 32(11):1065-84. PubMed ID: 26578430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Kadowaki T; Kondo K
    Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
    Rosenstock J; Aguilar-Salinas C; Klein E; Nepal S; List J; Chen R;
    Curr Med Res Opin; 2009 Oct; 25(10):2401-11. PubMed ID: 19650754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial.
    Chen Y; Liu X; Li Q; Ma J; Lv X; Guo L; Wang C; Shi Y; Li Y; Johnsson E; Wang M; Zhao J; Ji L
    Diabetes Obes Metab; 2018 Apr; 20(4):1044-1049. PubMed ID: 29144061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.
    Henry RR; Smith SR; Schwartz SL; Mudaliar SR; Deacon CF; Holst JJ; Duan RY; Chen RS; List JF
    Diabetes Obes Metab; 2011 Sep; 13(9):850-8. PubMed ID: 21554520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
    Handelsman Y; Mathieu C; Del Prato S; Johnsson E; Kurlyandskaya R; Iqbal N; Garcia-Sanchez R; Rosenstock J
    Diabetes Obes Metab; 2019 Apr; 21(4):883-892. PubMed ID: 30499237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score.
    Bonora E; Bryzinski B; Hirshberg B; Cook W
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):374-9. PubMed ID: 27033025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
    Rosenstock J; Hansen L; Zee P; Li Y; Cook W; Hirshberg B; Iqbal N
    Diabetes Care; 2015 Mar; 38(3):376-83. PubMed ID: 25352655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial.
    Dou J; Ma J; Liu J; Wang C; Johnsson E; Yao H; Zhao J; Pan C
    Diabetes Obes Metab; 2018 Mar; 20(3):590-598. PubMed ID: 28926170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centre, randomized, controlled trial.
    Gu T; Ma J; Zhang Q; Zhu L; Zhang H; Xu L; Cheng J; Shi B; Li D; Shao J; Sun Z; Zhong S; Bi Y; Zhu D
    Diabetes Obes Metab; 2019 Apr; 21(4):939-948. PubMed ID: 30520221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes.
    Rosenstock J; Gross JL; Aguilar-Salinas C; Hissa M; Berglind N; Ravichandran S; Fleming D
    Diabet Med; 2013 Dec; 30(12):1472-6. PubMed ID: 23802840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase.
    Kaku K; Mori M; Kanoo T; Katou M; Seino Y
    Expert Opin Pharmacother; 2014 Oct; 15(15):2121-30. PubMed ID: 25190226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.